Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of RSS0343 in Healthy Subjects
NCT07101965Phase 1Completed
- Sponsor
- Hengrui
- Start
- Apr 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RSS0343 in chronic rhinosinusitis without nasal polyps (CRSsNP) and chronic obstructive pulmonary disease (COPD) (8 arms), sponsored by Hengrui. Primary endpoint: Adverse events at Day 61. Started Apr 2024; status: completed.
02
Drugs
RSS0343
03
Conditions
chronic rhinosinusitis without nasal polyps (CRSsNP)chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07101965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07101965.